News|Articles|November 17, 2026

FDA Approves Neladalkib for Previously Treated ALK+ Lung Cancer

Fact checked by: CURE staff
Listen
0:00 / 0:00

Key Takeaways

  • Accelerated approval targets ALK-positive NSCLC with progression after alectinib or after at least two prior ALK TKIs plus platinum-based chemotherapy in unresectable locally advanced or metastatic settings.
  • ALKOVE-1 demonstrated ORR 49% post-alectinib (76% ≥6 months; 52% ≥12 months) and ORR 32% after ≥2 ALK TKIs plus chemotherapy (69% ≥6 months; 51% ≥12 months).
SHOW MORE

The FDA granted accelerated approval to Nelkarmi for adults with advanced ALK-positive non-small cell lung cancer that grew after prior ALK-targeted drugs.

The Food and Drug Administration (FDA) granted accelerated approval to Nelkarmi (neladalkib) for adults with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) that is locally advanced or has spread (metastatic) and has already been treated with other ALK-targeted drugs.

The approval, announced Nov. 17, covers patients with advanced disease that cannot be removed with surgery who previously received either alectinib (Alecensa), or two or more ALK-targeted drugs called tyrosine kinase inhibitors (TKIs) plus platinum-based chemotherapy.

Nelkarmi is a pill that blocks the ALK protein, which drives the growth of some lung cancers. Many ALK-positive lung cancers eventually stop responding to earlier ALK inhibitors, often because the cancer develops new mutations, leaving patients with fewer targeted options. CURE previously reported when the FDA submission for neladalkib was filed.

Accelerated approval allows the FDA to approve drugs for serious conditions based on early signs of benefit, such as tumor shrinkage. Continued approval may depend on results from a confirmatory trial. The application received priority review, and neladalkib was given breakthrough therapy and orphan drug designations.

Results From the ALKOVE-1 Trial

The approval is based on ALKOVE-1, a trial in which all patients received Nelkarmi. It included 67 patients previously treated with alectinib and 155 patients previously treated with two or more ALK inhibitors and platinum-based chemotherapy.

Among patients previously treated with alectinib, tumors shrank in 49%. Of those who responded, 76% had a response that lasted at least six months and 52% had a response that lasted at least a year.

Among patients who had received two or more ALK inhibitors and chemotherapy, tumors shrank in 32%. Of those who responded, 69% had a response that lasted at least six months and 51% had a response that lasted at least a year.

Possible Side Effects

The most common side effects, seen in at least 20% of patients, were liver problems, muscle and bone pain, constipation, changes in taste, nerve damage that can cause numbness or tingling (peripheral neuropathy), swelling (edema) and fatigue.

The prescribing information also warns about liver damage, kidney problems, eye problems, increases in creatine phosphokinase (an enzyme that can signal muscle damage) and possible harm to a developing baby. Patients should report any vision changes, unexplained muscle pain or weakness, or signs of liver trouble such as yellowing skin or dark urine, and should talk with their doctor about birth control during treatment.

How Nelkarmi Is Taken

The recommended dose of Nelkarmi is 150 mg by mouth once a day, with or without food, at about the same time each day. Treatment continues until the cancer grows or side effects become too difficult to manage.

Questions to Ask Your Care Team

  • Is Nelkarmi an option for me if my cancer grew on alectinib or another ALK inhibitor?
  • Should my tumor or blood be tested again to look for new mutations?
  • How will we monitor my liver, kidneys and eyes during treatment?
  • How does Nelkarmi compare with other options, such as chemotherapy or a clinical trial?

Learn more about ALK-positive lung cancer.

Reference

  1. “FDA grants accelerated approval to neladalkib for previously treated locally advanced or metastatic ALK-positive non-small cell lung cancer.” U.S. Food and Drug Administration. Nov. 17, 2026.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

For more news on cancer updates, research and education, don't forget to subscribe to CURE®'s newsletters here.


Related to this article